Neuro-Oncology Reviews
Volume
27 Number 25
10 September 2025
Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 25, 10 September
Ahamed C, Nguyen L, Brock CS, Farzamnia A, Millet P, Sato K, Kumar
KK.
Targeting the tumor
microenvironment in pediatric gliomas: Advances and future
directions in immunotherapy.
Neurooncol
Adv. 2025 Sep 1;7(1):vdaf193. doi:
10.1093/noajnl/vdaf193. PMID:
41030523. Review. ˍ
Fernández C, Ciérvide R, Díaz A, Garrido I,
Couñago F.
Radiotherapy in
Glioblastoma Multiforme: Evolution, Limitations, and Molecularly
Guided Future.
Biomedicines.
2025 Sep 1;13(9):2136. doi:
10.3390/biomedicines13092136. PMID:
41007699. Review. ˍ
Honeyman SI, Boukas A, Akhbari M, Okoli B, Stacey R,
Apostolopoulos V, Plaha P.
Awake
versus asleep craniotomy for eloquent glioblastoma: a systematic
review and meta-analysis.
Neurosurg
Rev. 2025 Sep 1;48(1):628. doi:
10.1007/s10143-025-03787-5. PMID:
40887547. Review;
Meta-analysis˰
ˍ
Serventi JN, Newton HB.
Tumor Treating
Fields: An Innovative Therapy for Glioblastoma and Other Solid
Tumors.
J
Adv Pract Oncol. 2025 Sep 1;16(5):181-191. doi:
10.6004/jadpro.2025.16.5.3. PMID:
41041265Review. ˍ
Jones G, Anderson JL, Nguyen PTT, Gleber-Netto FO, Hwang WL,
Puduvalli VK, Monje M, Amit M.
Novel
approaches to clinical trial design in cancer neuroscience.
Neuron.
2025 Sep 3;113(17):2791-2813. doi:
10.1016/j.neuron.2025.08.015. PMID:
40907474. Review˰
ˍ
Karreman MA, Winkler F.
Cancer
neuroscience of brain metastasis: When in Rome, do as the Romans
do.
Neuron.
2025 Sep 3;113(17):2740-2759. doi:
10.1016/j.neuron.2025.08.003. PMID:
40907472. Review. ˍ
Kazda T, Hnidakova L, Minniti G.
Reirradiation
in recurrent glioblastoma.
Curr
Opin Oncol. 2025 Sep 3;37(6):580-588. doi:
10.1097/CCO.0000000000001192. PMID:
41057143. Review.. ˍ
ˍ
*Monje M.
The neuroscience of brain
cancers.
Neuron.
2025 Sep 3;113(17):2734-2739. doi:
10.1016/j.neuron.2025.07.012. PMID:
40907471. Review. ˍ
Alsaedi MAH, Strathdee G.
The role of
DNA methylation in directing treatment in medulloblastoma.
Epigenomics.
2025 Sep 4:1-12. doi:
10.1080/17501911.2025.2554570. PMID:
40904269. Review˰
ˍ
Platten M.
Isocitrate dehydrogenase
mutation and microenvironment in gliomas: do immunotherapy
approaches matter?
Curr
Opin Neurol. 2025 Sep 4. doi:
10.1097/WCO.0000000000001426. PMID:
40916936. Review˰
ˍ
Zhang Y, Cheng Y.
Side effects of
boron neutron capture therapy.
J
Cancer Res Ther. 2025 Sep 4;21(4):777-786. doi:
10.4103/jcrt.jcrt_2743_23. PMID:
40905860. Review. ˍ
Ho A, Horbinski C, Sachdev S.
Thromboembolism
in gliomas: an under-recognized danger.
J
Neurooncol. 2025 Sep 5. doi:
10.1007/s11060-025-05204-9. PMID:
40913211. Perspective˰
ˍ
Scuderi SA, Ardizzone A, Calcaterra E, Palermo N, De Luca F,
Catalfamo A, Esposito E, Capra AP.
The
Gut-Brain Axis in Brain Tumors: Insights into Tumor Development,
Progression, and Therapy.
Biomedicines.
2025 Sep 5;13(9):2172. doi:
10.3390/biomedicines13092172. PMID:
41007735. Review. ˍ
van Loo KMJ, Bak A, Hodge R, Bedogni F, Ramirez JSB, Emerson SN,
Höllig A, Mansvelder HD, Goriounova NA, Ramirez JM, Koch H.
What makes the human brain special:
from cellular function to clinical translation.
J
Neurophysiol. 2025 Sep 5;134(4):1197-1213. doi:
10.1152/jn.00120.2025. PMID:
40912899. Review. ˍ
Zhang H, Li Y.
Temozolomide-Derived
Therapeutic Strategies to Overcome Resistance in Glioblastoma.
J
Med Chem. 2025 Sep 6;68(18):18810-18828. doi:
10.1021/acs.jmedchem.5c02019. PMID:
40913573. Review˰
ˍ
Manzano-Benito I, Riveiro-Vicente L, Sánchez-Muñoz
C, Bartolomé-Asensio I, Mollejo M, Meléndez B.
Unraveling the Molecular Basis of
Extracranial Glioblastoma Metastasis: A Case Report and Literature
Review.
Neuropathology.
2025 Sep 7;45(5):e70025. doi:
10.1111/neup.70025. PMID:
40915661. Review˰
ˍ
Habibi MA, Nejati N, Najafi MB, Khodadadiyan A, Dashti M,
Lorestani P, Karimizadeh Z, Ahmadpour M, Kalantari A, Jokar-Derisi
A, Maghsood F, Robat-Jazi B, Ebrahimi E, Ahmadpour S, Tavakolpour
S.
Enhancing T cell infiltration in
glioblastoma: a review article on challenges and therapeutic
strategies.
Cancer
Treat Res Commun. 2025 Sep 9;45:100999. doi:
10.1016/j.ctarc.2025.100999. PMID:
40961824. Review. ˍ
Hansen LJ, Jackson CM.
The glioma
microenvironment and its impact on antitumor immunity.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv19-iv31. doi:
10.1093/noajnl/vdae204. PMID:
40933033. Review. ˍ
Hill CM, Wang AZ, Hsueh B, Ramirez R, Sherpa N, Costa M, Williams
O, Li M, Dunn GP.
Immunologic
specificity in glioblastoma: Antigen discovery and translational
implications.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv41-iv70. doi:
10.1093/noajnl/vdaf028. PMID:
40933038. Review. ˍ
Jha R, Spanehl L, Chen JA, Gessler FA, Arnaout O, Valdes PA, Choi
BD, Peruzzi PP, Bernstock JD, Chiocca EA.
Translational
advancements in tumor vaccine therapies for glioblastomas.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv72-iv83. doi:
10.1093/noajnl/vdaf051. PMID:
40933034. Review. ˍ
Landry AP, Ellenbogen Y, Ajisebutu A, Gui C, Gao A, Nassiri F,
Zadeh G.
Biomarkers of immunotherapy
response in neuro-oncology.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv32-iv40. doi:
10.1093/noajnl/vdaf104. PMID:
40933032. Review. ˍ
Lang X, Zhang S, Wang Y.
Targeting the
neuroimmune axis in glioblastoma: emerging strategies for
precision immunotherapy.
Front
Immunol. 2025 Sep 9;16:1661327. doi:
10.3389/fimmu.2025.1661327. PMID:
40995359. Review. ˍ
Puviindran BJ, Wallace S, Ayasoufi K, Lerner E, Fecci PE.
Within
and beyond the tumor: Mechanisms of glioblastoma-induced
immunosuppression.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv4-iv18. doi:
10.1093/noajnl/vdaf006. PMID:
40933031. Review. ˍ
Scott BJ, Monje M.
Cellular
immunotherapies for central nervous system cancers.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv84-iv94. doi:
10.1093/noajnl/vdaf120. PMID:
40933036. Review. ˍ